zavegepant   Click here for help

GtoPdb Ligand ID: 11513

Synonyms: BHV-3500 | BMS-742413 | BMS742413 | Zavzpret®
Approved drug
zavegepant is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Zavegepant is a CGRP receptor antagonist [1-2], that was developed as a drug to treat and/or prevent migraine. It was designed for intranasal administration.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 120.67
Molecular weight 638.37
XLogP 3.56
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN1CCC(CC1)N1CCN(CC1)C(=O)[C@H](NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O)Cc1cc(C)c2c(c1)cn[nH]2
Isomeric SMILES CN1CCC(CC1)N1CCN(CC1)C(=O)[C@H](NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O)Cc1cc(C)c2c(c1)cn[nH]2
InChI InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Zavegepant (as BHV-3500) was evaluated as a migraine prophylactic drug by Biohaven Pharmaceuticals. It was the first CGRP receptor antagonist nasal spray for the acute treatment of migraine, with its FDA approval granted in March 2023.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04408794 Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT04571060 Randomized Trial in Adult Subjects With Acute Migraines Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT04346615 Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT03872453 Acute Treatment Trial in Adult Subjects With Migraines Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT04804033 A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.